Evgen Pharma Share Discussion Threads

[moneymunch] 15/6/2020 13:06

Maybe news on potential funding for Covid-19 is still possible. Gl ;-)


Potential new treatment approach to fatal COVID-19

May 18 2020

Researchers from the University of Colorado Anschutz Medical Campus and Pathways Bioscience in the United States have found that activating a transcription factor involved in oxidative stress regulation, antiviral activity, and inflammation may serve as a new treatment approach to coronavirus disease 2019 (COVID-19).

The scientists propose that the antiviral and anti-inflammatory effects of activating nuclear factor erythroid 2-related factor 2 (Nrf2) may reduce symptoms and stop the “cytokine storm syndrome” that can be fatal in cases of COVID-19.



................

15/6/20

Announcing today’s results, executive chairman Barry Clare said: “We move forward with the confidence that the value of SFX-01 as a potential drug that is active against the two key pathways of Nrf2 and STAT3 will become increasingly clear.

“These pathways are of significance in a range of diseases including cancer, autism and those where oxidative stress is a factor.

“We, therefore, believe that the fundamentals are in place to underpin sustainable share price growth and deliver the undoubted potential of SFX-01.

[lovewinshatelosses] 15/6/2020 11:26

I agree, Peanut. Am surprised it has not fallen further, but I guess the optimistic jam tomorrow tone has done enough - for now. Either those talks are still ongoing or are dead in the water, but to not update the market on this fairly significant matter is unimpressive. Hopefully the drug will more than compensate holders nevertheless. GLA.

[peanut100] 15/6/2020 10:59

How can they not give any update following the Covid news a month ago - absolutely shocking

[lionheart69uk] 15/6/2020 10:31

Watching it continue to fall and may pounce at 8p later this week

[lionheart69uk] 15/6/2020 10:31

Still looking at 15p by the end of the year.

[moneymunch] 15/6/2020 09:39

Well i suppose they had to get the Final Results released, and so any good news in the pipeline will now surely follow. Gl ;-)

[moneymunch] 15/6/2020 09:06

Looks like a few are happy to give up their shares cheaply, and hopefully will regret it soon enough...Gla ;-)

[moneymunch] 15/6/2020 08:06

News of the appointment of a new CEO must be close, additional positive news on potential funding etc could drop at anytime. Gla ;-)

[lionheart69uk] 15/6/2020 07:45

Stock market will crash today so be warned.

[moneymunch] 15/6/2020 07:42

We are embarking on a campaign to source non-dilutive funds for a follow-on placebo-controlled randomised trial in ER+ metastatic breast cancer, to generate the data that would maximise the likelihood of a corporate partnership/out-licensing deal. Such funding may be sourced from direct grants, cancer charities or possibly via investigator-led trials.

[moneymunch] 15/6/2020 07:41

Upbeat and confident Results. Gla ;-)

Our strategy is to move to a business model where we facilitate multiple clinical trials on SFX-01 in risk-sharing arrangements, with the objective of attracting non-dilutive funding from grants and/or charities to wholly or substantially fund future clinical activity. This strategy has three key components:

(1) Our first priority is to ensure the continued development of the breast cancer programme. We will complete the trial design and cost a clinical trial protocol and then seek non-dilutive funding for Evgen and/or an affiliated clinical institution to sponsor the trial.

(2) In parallel we aim to leverage the extensive pre-clinical and clinical data that shows the potential for SFX-01, as a sulforaphane delivery platform, to be used in diseases that are beyond our capacity to pursue.

(3) In addition, we will pursue opportunities to apply our intellectual property on stabilised sulforaphane to non-pharmaceutical opportunities which offer a more rapid route to market.

We will therefore support a number of proposed Investigator-Initiated Trials - these are trials led by a clinician from a well-renowned institution, with that institution being the sponsor for the trial. Evgen will provide support as required (in the confines of an investigator sponsored study), sharing our knowledge, experience and the methods and laboratories used for pharmacodynamic and pharmacokinetic endpoints. All such trials are subject to grant funding being procured and Evgen will supply clinical centres with SFX-01 and, where appropriate, a placebo.

Evgen will have the right to access the clinical data on fair commercial terms to advance its clinical and commercial development. Since the principal funding for these trials will be obtained by the investigator/ institution they have limited impact on our cash reserves.

We have announced three Memorandums of Understanding relating to further potential trials in non-alcoholic steatohepatitis, chronic kidney disease and autism, and are in discussions for others. We are hopeful that at least one of these will be awarded a grant so as to commence in H2 this year or H1 2021.

Finally, we are now in a period where we are using funds from the last investment round to complete the technical package required to support this strategy. This involves investment in Chemistry, Manufacturing and Controls ("CMC") in developing a tablet formulation for world-wide distribution to multiple clinical centres, and investment in the toxicology package to be able to support trials of longer dosing duration (i.e. over 28 days). By the time this CMC investment period is complete, we could initiate a portfolio of clinical trials such as those described above.

We believe this strategy offers the best route to enhance shareholder value and the opportunity for all stakeholders to benefit from the undoubted potential of SFX-01 and our broader technology platform.

[toffeeman] 15/6/2020 07:24

Absolutely jack sh1t news

[moneymunch] 15/6/2020 07:01

Evgen Pharma plc

(the "Company")



Final Results

Evgen Pharma plc (AIM: EVG), the clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases, announces its final results for the year ended 31 March 2020.

Operational highlights

· Positive results from the STEM trial of SFX-01 in metastatic breast cancer presented at European Society of Medical Oncology Congress in Barcelona, demonstrating the stabilisation of previously progressive disease and objective responses in some patients

· Five patients who participated in the STEM trial received SFX-01 treatment for over one year with no tumour progression

· Results from the SFX-01 After Subarachnoid Haemorrhage ("SAS") trial did not meet primary or secondary efficacy endpoints, however the treatment was well tolerated with no safety concerns, supporting evaluation in other indications

· Significant progress made in tablet formulation of SFX-01 that will underpin easier clinical use in a range of indications and yield economic and production benefits

· Memorandums of Understanding reached with Guy's and St Thomas' NHS Foundation Trust, University of Dundee and University of Rochester (NY) to support clinical trials of SFX-01 in autism, non-alcoholic steatohepatitis and chronic kidney disease, respectively

· Research collaboration with King's College London and the British Heart Foundation to investigate how SFX-01 mediates upregulation of Nrf2 in the blood-brain barrier endothelium in-vivo



Post period end highlights

· Publication in Oncogene of preclinical data for SFX-01's role in targeting STAT3 signalling and inhibition of endocrine resistant stem-like cells in ER-positive breast cancer



Financial highlights

· Financial performance in-line with expectations:

o Post tax loss of £2.7m (2019: loss of £2.6m)

o Cash outflow from operations of £2.6m (2019: outflow of £2.3m)

o Cash balance at 31 March 2020 of £4.1m (31 March 2019: £2.0m)

· Oversubscribed fundraising in May 2019 raised £5.0m before expenses



Barry Clare, Executive Chairman of Evgen Pharma, said: "We move forward with the confidence that the value of SFX-01 as a potential drug that is active against the two key pathways of Nrf2 and STAT3 will become increasingly clear. These pathways are of significance in a range of diseases including cancer, autism and those where oxidative stress is a factor. We therefore believe that the fundamentals are in place to underpin sustainable share price growth and deliver the undoubted potential of SFX-01. On behalf of myself and the Board, I would like to thank our shareholders for their continued support and we look forward to updating the market with positive news in the coming year."

[moneymunch] 12/6/2020 08:36

A nice 100k buy at 11p.....fingers crossed for more of the same in anticpation that the Final Results will make good reading first thing Monday morning. Gla ;-)

[moneymunch] 12/6/2020 08:08

Researchers have found that sulforaphane reduced the expression of long noncoding RNAs (lncRNAs) in prostate cancer cells, which disrupted the cells’ ability to form colonies – a hallmark of metastatic cancer.

Previously believed to be “junk DNA” with no significant function, lncRNAs have increasingly emerged as key players in the development of numerous cancers, including prostate, breast, stomach, and lung cancers.

Studies have suggested that lncRNAs can regulate gene expression – the process by which genes are switched on or off in order to do their jobs. When lncRNAs become dysregulated, it is believed that they can fuel disease development.

Not only does the new study provide further evidence of the role lncRNAs play in cancer, but it supports previous research hailing the anticancer effects of sulforaphane.

[moneymunch] 11/6/2020 18:30

Something similar with Evgen would be marvellous, and there appears to be an interaction between Sulphorphane and RNA, as well as Evgen's stunning phase 11 breast cancer results that could be of great interest to AstraZeneca. Gl :-)


www.researchgate.net/publication/277883789_

Interaction_of_sulforaphane_with_DNA_and_RNA





4/6/20

Dive Brief:

AstraZeneca will pay privately held Accent Therapeutics $55 million in a deal to develop cancer drugs that target enzymes which can modify RNA molecules.Lexington, Massachusetts-based Accent will handle the early research and development work under the deal, before handing those responsibilities off to AstraZeneca after Phase 1 testing. The biotech could receive up to $1.1 billion in additional cash from AstraZeneca, though those dollars are tied to various milestones.Accent is one member of a group of companies that are using chemical-based drugs to target RNA. It's at least the third such company to form a partnership with a large drugmaker, following similar pacts featuring Arrakis Therapeutics and Skyhawk Therapeutics.

Dive Insight:

Interfering with RNA — the molecules that turn genetic instructions into proteins — comes with great promise, because it gives drugmakers a way to try to control the expression of specific genes. But doing so with small molecules has long only been achieved accidentally, and is thought to be a tough task because RNA molecules constantly shapeshift and move freely inside cells.

Other methods of disrupting RNA sequences — such as the approaches used by Alnylam Pharmaceuticals and Ionis Pharmaceuticals — emerged first. After years of ups and downs, both companies have brought to market drugs to treat transthyretin amyloidosis, spinal muscular atrophy, and other diseases, over the past few years.

Their progress validated new ways to develop medicines and led to a flurry of deals between RNA drug developers and pharmaceutical companies, which have shown renewed interest after abandoning the field years ago. AstraZeneca is among them: in March, it put $80 million into Silence Therapeutics to develop RNA-based drugs for heart, kidney, lung and other diseases.

Now, however, increasing understanding about RNA biology has also led to a new group of venture-backed startups that aim to use chemical-based compounds to drug RNA. A number of them, including Accent, Arrakis, Skyhawk, Gotham Therapeutics and Expansion Therapeutics, have started up and raised cash from venture firms since 2017.

Though these privately held startups are much earlier in their work than the likes of Alnylam and Ionis, pharmaceutical companies have already shown interest. In April, Roche paid $190 million to start a wide-ranging deal with Arrakis. Skyhawk is working with Merck & Co., Biogen and others.

Accent is specifically focused on cancer therapies, and even more narrowly, drugging enzymes that modify RNA molecules. RNAs use these enzymes to make chemical changes to alter their structure and function, which, in turn, affects how much of a particular protein they produce.

Accent aims to find and selectively block enzymes that might, for instance, lead to the production of proteins that drive tumor growth. A 2018 paper published in Nature Reviews Drug Discovery ̵2; co-authored by Accent president and chief scientific officer Bob Copeland — highlights some of the RNA-modifying enzymes believed to be implicated in cancer. Among them is an enzyme, METTL3/14, that Accent is pursuing as a potential drug target for the blood cancer acute myeloid leukemia.

Accent will conduct the initial research and development for any drug prospects that emerge from the deal, and hand things off to AstraZeneca following Phase 1 testing. Accent will get the option to split U.S. rights, as well as the costs of development, of each program afterwards. AstraZeneca does get the exclusive option to grab worldwide rights to two Accent programs, however.

[mesquida] 11/6/2020 18:19

This held up relatively well today given that it was such a poor day for small caps. But volume here was very low so perhaps there are no conclusions to be drawn. Whatever, on Monday we surely should hear something about the potential investment partnership.

[moneymunch] 11/6/2020 10:01

Lol...i'm hoping it's a share code for stellar Rns imminent...;-)))

[toffeeman] 11/6/2020 09:56

Promise you it wasn't me

[moneymunch] 11/6/2020 09:52

11p paid for 150 shares!!! ;-)

[peanut100] 10/6/2020 14:15

Hope so - what a prime opportunity to announce all this ASAP

[moneymunch] 10/6/2020 12:51

Hence the suggestion of smoke screen, there's every chance that SFX-01 could be a potential treatment for Covid-19, but the phase 11 trial data for breast cancer was outstanding and "life changing for some patients ", and so the incredible strong links with AstraZeneca through the long standing research collaboration with University of Manchester and confirmation that in combination SFX-01 improves clinical outcome of Astrazeneca's two blockbuster cancer drugs, could be pivotal to proceedings , and so hopefully an update in time or with the Final Results this coming Monday. Gla :-)

[peanut100] 10/6/2020 10:17

And no more news on 'the potential source of funds that would help pay for a clinical trial in covid-19 patients, with Evgen providing SFX-01 in support of such a trial', that was nearly a month ago. Very poor details then and nothing since. This virus will be long gone by the time they say anymore about it. You either have funding or you don't. Must be pretty easy to update the market with this after days not weeks or months.

[bumpa33] 10/6/2020 09:52

6 weeks on, with each day that passes increasingly less likely we’ll be getting a new CEO, an independent one anyway. I’m also leaning towards smokescreen.